Updated:
FundRx
FundRx is a Nashville venture firm that backs clinician-founders at pre-seed, sourcing healthcare deals through a network of practicing physicians.
FundRx
FundRx operates from Nashville, a city that has quietly become a healthcare services nerve center. The firm is built on the thesis that the best healthcare founders are clinicians who still practice — surgeons, internists, and specialists who see workflow inefficiencies firsthand. Rather than running a public application process or demo day, FundRx relies on a network of physician-entrepreneurs to surface early-stage companies, selecting a small number per year for concentrated pre-seed investment. The firm writes initial checks into companies spanning digital health, medical devices, diagnostics, and care-delivery platforms. Stage coverage begins at pre-seed and often extends through seed with follow-on reserves. FundRx typically structures investments as direct equity deals and frequently brings in co-investors from its network of domain-expert angels and specialist venture funds. Geographic reach includes companies across the United States, with particular density in healthcare-heavy markets like Nashville, Boston, and the Bay Area. Team size and total deployment remain undisclosed. The firm does not operate a fund-of-funds or publicly list adjacent vehicles such as philanthropic foundations or real-asset arms. No recent fund closing or major operational event has been publicly confirmed in the last 24 months. FundRx's structural differentiator is its embedded-sourcing model: the firm recruits practicing physicians as scouts and venture partners, turning clinical workflows into a proprietary deal pipeline. This bypasses the internet-scraping and demo-day filtering that most healthcare pre-seed investors rely on, giving FundRx access to companies that often raise their first outside capital before they appear on any database.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Nashville
Corporate office
Nashville, TN, United States
Sector focus
Frequently asked questions
Who runs investment decisions at FundRx?
FundRx does not publicly disclose a named CIO or managing partner list. Based on public record, the firm operates through a network of physician venture partners who source and diligence deals, with final investment decisions made by a central partnership group in Nashville. Specific names and titles have not been confirmed through the firm's own communications.
How does FundRx source proprietary deal flow?
FundRx sources deals through a network of practicing clinicians who act as scouts and venture partners. These physicians encounter early-stage healthcare companies through their own clinical practice — seeing products, devices, or software workflows before they reach pitch decks or accelerators. This embedded-sourcing model gives the firm access to companies that often have not formally fundraised.
Does FundRx participate in fund commitments or only direct deals?
FundRx is structured for direct pre-seed and seed equity investments, not as a fund-of-funds. There is no public record of the firm making LP commitments into other venture funds. Its model is to write first checks directly into operating companies, then syndicate with domain-expert angels and specialist healthcare funds on follow-on rounds.
What investment stages does FundRx typically target?
The firm targets pre-seed and seed-stage companies. FundRx's thesis is to invest at the earliest institutional entry point — often before a startup has revenue, a full team, or regulatory clearance — and reserve capital for follow-on participation through later seed rounds. The firm does not publicly lead growth-stage or late-stage rounds.
Which sectors does FundRx explicitly avoid?
FundRx has not published an explicit exclusion list. Based on its investment activity, the firm does not invest in non-healthcare sectors such as enterprise SaaS, fintech, or consumer internet. Within healthcare, there is no public indication that the firm avoids regulated medical devices or diagnostics, but payer-facing or pharma-services deals have not been prominently featured in its known portfolio.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: